Panel Discussion: Pharma & VC Perspectives on ASIT: Leveraging Early Safety Signals & Differentiated Platforms to Guide Investment & Strategic Partnerships
- How do VCs and strategic partners assess differentiation among ASIT companies using nanoparticles, cell-based
- What development milestones -such as proof of infectious or bystander tolerance, early human safety signals, or scalable manufacturing – most strongly influence investment and partnership decisions?
- What do pharma see as the future challenges in the ASIT space?